

QuantiGene® 2.0 Bibliography

2014

1. Berhanu T. K., *et al.* Increased AMP-activated protein kinase in skeletal muscles of Murphy Roth Large mice and its potential role in altered metabolism. *Physiological Reports* **2**(3) (2014).
2. Bowling A. J., Pence H. E. and Church J. B. Application of a Novel and Automated Branched DNA in Situ Hybridization Method for the Rapid and Sensitive Localization of mRNA Molecules in Plant Tissues. *Applications in Plant Sciences* **2**(4):1400011 (2014).
3. Dong Y., *et al.* Lipid-Like Nanomaterials for Simultaneous Gene Expression and Silencing In Vivo. *Adv Healthc Mater* (2014).
4. Dubelman S., *et al.* Environmental Fate of Double-Stranded RNA in Agricultural Soils. *PLoS ONE* **9**(3):e93155 (2014).
5. Rice E. A., *et al.* Expression of a Truncated ATHB17 Protein in Maize Increases Ear Weight at Silking. *PLoS ONE* **9**(4):e94238 (2014).
6. Sandoz K. M., *et al.* Developmental transitions of Coxiella burnetii grown in axenic media. *J Microbiol Methods* **96**:104-10 (2014).
7. Sinnamon J. R. and Czaplinski K. RNA detection in situ with FISH-STICs. *RNA* **20**(2):260-6 (2014).
8. Takeuchi K., *et al.* EGF-Like-Domain-7 Is Required for VEGF-Induced Akt/ERK Activation and Vascular Tube Formation in an Ex Vivo Angiogenesis Assay. *PLoS ONE* **9**(3):e91849 (2014).
9. Voss C., *et al.* A novel, non-radioactive eukaryotic in vitro transcription assay for sensitive quantification of RNA polymerase II activity. *BCM Mol Biol* **15**(1):7 (2014).
10. Xue L., *et al.* Prostaglandin D2 activates group 2 innate lymphoid cells through chemoattractant receptor-homologous molecule expressed on TH2 cells *J Allergy Clin Immunol* (2014).
11. Zhang Y., *et al.* Effect of various antibiotics on modulation of intestinal microbiota and bile acid profile in mice. *Toxicol Appl Pharmacol* (2014).

2013

1. Boess F., *et al.* Effect of GLP-1R agonists taspoglutide and liraglutide on primary thyroid C-cells. *J Mol Endocrinol* (2013).
2. Bonnet M. E., *et al.* Systemic delivery of sticky siRNAs targeting the cell cycle for lung tumor metastasis inhibition. *J Control Release* (2013).
3. Chapuis J., *et al.* Increased expression of BIN1 mediates Alzheimer genetic risk by modulating tau pathology. *Mol Psychiatry* (2013).

QuantiGene® 2.0 Bibliography

4. Chen K., *et al.* Value of circulating cell-free DNA in diagnosis of hepatocellular carcinoma. *World J Gastroenterol* **19**(20):3143-9 (2013).
5. Cheng Z., *et al.* A novel, sensitive assay for high-throughput molecular detection of plasmodia for active screening of malaria for elimination. *J Clin Microbiol* **51**(1):125-30 (2013).
6. Crevecoeur J., *et al.* Expression pattern of synaptic vesicle protein 2 (SV2) isoforms in patients with temporal lobe epilepsy and hippocampal sclerosis. *Neuropathol Appl Neurobiol* (2013).
7. Erba H. P., *et al.* Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML). *Invest New Drugs* (2013).
8. Esposito G., *et al.* Palmitoylethanolamide improves colon inflammation through an enteric glia/toll like receptor 4-dependent PPAR-alpha activation. *Gut* (2013).
9. Hazalin N. A., *et al.* Apoptosis induced by desmethyl-lasiodiplodin is associated with upregulation of apoptotic genes and downregulation of monocyte chemotactic protein-3. *Anti-Cancer Drugs* (2013).
10. Keding V., *et al.* Sticky siRNAs targeting survivin and cyclin B1 exert an antitumoral effect on melanoma subcutaneous xenografts and lung metastases. *BMC Cancer* **13**(338) (2013).
11. Kovacs T., Kelemen O. and Keri S. Decreased fragile X mental retardation protein (FMRP) is associated with lower IQ and earlier illness onset in patients with schizophrenia. *Psychiatry Res* (2013).
12. Liu H., *et al.* Association study of TOLL and CARD with leprosy susceptibility in Chinese population. *Hum Mol Genet* (2013).
13. Lutter E. I., *et al.* Chlamydia trachomatis Inclusion Membrane Protein CT228 Recruits Elements of the Myosin Phosphatase Pathway to Regulate Release Mechanisms. *Cell Rep* (2013).
14. Maier M. A., *et al.* Biodegradable Lipids Enabling Rapidly Eliminated Lipid Nanoparticles for Systemic Delivery of RNAi Therapeutics. *Mol Ther* (2013).
15. Mazzuferi M., *et al.* Nrf2 defense pathway: Experimental evidence for its protective role in epilepsy. *Ann Neurol* (2013).
16. Mercken E. M., *et al.* Calorie restriction in humans inhibits the PI3K/AKT pathway and induces a younger transcription profile. *Aging Cell* (2013).
17. Miura D., Iwatani T. and Kawabata H. Mechanisms of primary AI resistance in ER-positive HER2-negative breast cancer. *2013 ASCO Annual Mtg Proc (Post-Meeting Edition)* **31**(15, May 20 Sup):E11519 (2013).
18. Mukund S., *et al.* Inhibitory mechanism of an allosteric antibody targeting the glucagon receptor. *J Biol Chem* **288**(50):36168-78 (2013).
19. Ooi Y. S., *et al.* Genome-wide RNAi screen identifies novel host proteins required for alphavirus entry. *PLoS Pathog* **9**(12):e1003835 (2013).

QuantiGene® 2.0 Bibliography

20. Patel P. R., *et al.* Genomic Signature Predicts Resistance To Busulfan In AML Cell Lines. *Blood* **122**(21):3850 (2013).
21. Piccinni M. P., *et al.* Potential pathogenetic role of Th17, Th0, and Th2 cells in erosive and reticular oral lichen planus. *Oral Dis* (2013)
22. Plovanich M., *et al.* MICU2, a paralog of MICU1, resides within the mitochondrial uniporter complex to regulate calcium handling. *PLoS ONE* **8**(2):e55785 (2013).
23. Sahay G., *et al.* Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling. *Nat Biotechnol* (2013).
24. Storey K. B. and Wu C. W. Stress response and adaptation: A new molecular toolkit for the 21st century. *Comp Biochem Physiol A Mol Integr Physiol* (2013).
25. Trabzuni D., *et al.* Fine-Mapping, Gene Expression and Splicing Analysis of the Disease Associated LRRK2 Locus. *PLoS ONE* **8**(8):e70724 (2013).
26. Zhang M., *et al.* Alteration of circulating mitochondrial DNA concentration after irradiation. *Adv Exp Med Biol* **765**(371-7) (2013).
27. Zurek O. W., *et al.* The Role of Innate Immunity in Promoting SaeR/S-Mediated Virulence in Staphylococcus aureus. *J Innate Immun* (2013).

2012

1. Burgess A., *et al.* Focused ultrasound for targeted delivery of siRNA and efficient knockdown of Htt expression. *J Control Release* (2012).
2. Cheng X. & Klasseen C. D. Hormonal and chemical regulation of paraoxonases in mice. *J Pharmacol Exp Ther* **342**(3):688-95 (2012).
3. Cheng Z., *et al.* Towards Active Screening of Malaria for Elimination: A Novel, Sensitive Assay for High Throughput Molecular Detection of Plasmodia. *J Clin Microbiol* (2012).
4. Conforto T. L., *et al.* Impact of CUX2 on the Female Mouse Liver Transcriptome: Activation of Female-biased Genes and Repression of Male-biased Genes. *Mol Cell Biol* (2012).
5. Cui J. Y., *et al.* Bile acids via FXR initiate the expression of major transporters involved in the enterohepatic circulation of bile acids in newborn mice. *Am J Physiol Gastrointest Liver Physiol* (2012).
6. Desai A., *et al.* META060 attenuates TNF-alpha-activated inflammation, endothelial-monocyte interactions, and matrix metalloproteinase-9 expression, and inhibits NF-kappaB and AP-1 in THP-1 monocytes. *Atherosclerosis* **223**(1):130-6 (2012).
7. Dunmore R., *et al.* An assessment of epithelial and mesenchymal phenotypes in experimental and clinical pulmonary fibrosis. *ISRN Pulmonology* **Volume 2012** (2012).
8. Foster D. J., *et al.* Comprehensive evaluation of canonical versus Dicer-substrate siRNA in vitro and in vivo. *Rna* **18**(3):557-68 (2012).

QuantiGene® 2.0 Bibliography

9. Hummon A. B., *et al.* Systems-wide RNAi analysis of CASP8AP2/FLASH shows transcriptional deregulation of the replication-dependent histone genes and extensive effects on the transcriptome of colorectal cancer cells. *Molecular Cancer* **11**(1) (2012).
10. Jiao X., *et al.* Discovery and optimization of a series of liver X receptor antagonists. *Bioorg Med Chem Lett* **22**(18):5966-70 (2012).
11. Kim H. R., *et al.* Fibroblast Growth Factor Receptor 1 Gene Amplification Is Associated With Poor Survival and Cigarette Smoking Dosage in Patients With Resected Squamous Cell Lung Cancer. *J Clin Oncol* (2012).
12. Koth C. M., *et al.* Molecular basis for negative regulation of the glucagon receptor. *Proc Natl Acad Sci USA* **109**(36):14393-8 (2012).
13. Li X., *et al.* [Angiotensin (1-7) inhibits angiotensin II-stimulated expression of connective tissue growth factor mRNA in hepatic stellate cells.] *Zhonghua Gan Zang Bing Za Zhi* **20**(6):458-62 (2012).
14. Linton K., *et al.* Microarray gene expression analysis of fixed archival tissue permits molecular classification and identification of potential therapeutic targets in diffuse large B-cell lymphoma. *J Mol Diagn* **14**(3):223-32 (2012).
15. Meng X. L., *et al.* Low expression of stathmin in tumor predicts high response to neoadjuvant chemotherapy with docetaxel-containing regimens in locally advanced breast cancer. *Genet Test Mol Biomarkers* (2012).
16. Metzgera D. C., *et al.* Normalizing for biology: Accounting for technical and biological variation in levels of reference gene and insulin-like growth factor 1 (igf1) transcripts in fish livers. *Comp Biochem and Physiol* (2012).
17. Mounier A., *et al.* Genetic complexity in the BIN1 locus. *Journal of the Alzheimers Association* **8**(1, Supp.):P663-4 (2012).
18. Muller P., Pugazhendhi D., Ziedler M. P. Modulation of human JAK-STAT pathway signaling by functionally conserved regulators. *JAK-STAT* **1**(1):1-11 (2012).
19. Patani R., *et al.* Investigating the utility of human embryonic stem cell-derived neurons to model ageing and neurodegenerative disease using whole-genome gene expression and splicing analysis. *J Neurochem* **122**(4):738-51 (2012).
20. Pettersen J. C., *et al.* The PPARalpha agonists fenofibrate and CP-778875 cause increased beta-oxidation, leading to oxidative injury in skeletal and cardiac muscle in the rat. *Toxicol Pathol* (2012).
21. Phan J. H., Quo, C. F. & Want, M. D. Cardiovascular genomics: a biomarker identification pipeline. *IEEE Trans Inf Technol Biomed* **16**(5):809-22 (2012).
22. Qi J., *et al.* The use of stable isotope-labeled glycerol and oleic acid to differentiate the hepatic functions of diacylglycerol acyltransferase-1 and -2. *J Lipid Res* (2012).
23. Querbes W., *et al.* Treatment of erythropoietin deficiency in mice with systemically administered siRNA. *Blood* **120**(9):1916-22 (2012).
24. Ruangsiriluk W., *et al.* Silencing of enzymes involved in ceramide biosynthesis causes distinct global alterations of lipid homeostasis and gene expression. *J Lipid Res* (2012).

QuantiGene® 2.0 Bibliography

25. Sarveswaran J., *et al.* Cytokine gene expression profiling identifies distinct patterns in severe sepsis. *Nucleic Acid Ther* **22**(5):344-59 (2012).
26. Schneider B., *et al.* Targeted siRNA delivery and mRNA knockdown mediated by bispecific digoxigenin-binding antibodies. *Mole Ther Nucleic Acids* **1**(9):e46 (2012).
27. Schwartz J. R., *et al.* A facile, branched DNA assay to quantitatively measure glucocorticoid receptor auto-regulation in T-cell acute lymphoblastic leukemia. *Chin J Cancer* **31**(8):381-91 (2012).
28. Sciabola S., *et al.* Improved nucleic acid descriptors for siRNA efficacy prediction. *Nucleic Acids Res* (2012).
29. Shahnazari M., *et al.* Bone turnover markers in peripheral blood and marrow plasma reflect trabecular bone loss but not endocortical expansion in aging mice. *Bone* **50**(3):628-37 (2012).
30. Siah A., Johnson, G. & Berthe, F. C. Single Plex Branched DNA as an Alternative Assay to Quantify P53-Like mRNA Levels in Softshell Clam *Mya arenaria* Hemocytes. *Journal of Shellfish Research* **31**(3):691-96 (2012).
31. Stanton R., *et al.* Chemical modification study of antisense gapmers. *Nucleic Acid Ther* **22**(5):344-59 (2012).
32. Tanguy M., *et al.* Functional and molecular responses in *Mytilus edulis* hemocytes exposed to bacteria, *Vibrio splendidus*. *Dev Comp Immunol* (2012).
33. Trabzuni D., *et al.* MAPT expression and splicing is differentially regulated by brain region: relation to genotype and implication for tauopathies. *Hum Mol Genet* **21**(18):4094-103 (2012).
34. Wen X., *et al.* Regulation of hepatic phase-II metabolism in pregnant mice. *J Pharmacol Exp Ther* (2012).
35. Zhang L., *et al.* Radiation-induced elevation of plasma DNA in mice is associated with genomic background. *Adv Exp Med Biol* **737**:147-53 (2012).
36. Zhang Y., *et al.* Dysfunction of organic anion transporting polypeptide 1a1 alters intestinal bacteria and bile Acid metabolism in mice. *PLoS ONE* **7**(3):e34522 (2012).
37. Zhang Y., *et al.* Transcription factor-mediated regulation of carboxylesterase enzymes in livers of mice. *Drug Metab Dispos* (2012).

2011

1. Babij C., *et al.* STK33 kinase activity is nonessential in KRAS-dependent cancer cells. *Cancer Res* (2011).
2. Baughman J. M., *et al.* Integrative genomics identifies MCU as an essential component of the mitochondrial calcium uniporter. *Nature* (2011).
3. Beare P. A., *et al.* Dot/Icm Type IVB secretion system requirements for *Coxiella burnetii* growth in human macrophages. *MBio* **2**(4) (2011).
4. Bergemann T. L., Wilson J. Proportion statistics to detect differentially expressed genes: a comparison with log-ratio statistics. *BMC Bioinformatics* **12**(1):228 (2011).

QuantiGene® 2.0 Bibliography

5. Brown M. L., *et al.* Discovery of amide replacements that improve activity and metabolic stability of a bis-amide smoothed antagonist hit. *Bioorg Med Chem Lett* **21**(18):5206-9 (2011).
6. Cao G., *et al.* Evacetrapib is a novel, potent and selective inhibitor of cholesteryl ester transfer protein that elevates high-density lipoprotein cholesterol without inducing aldosterone or increasing blood pressure. *Journal of Lipid Research* (2011).
7. Cao Y. C., *et al.* Quantum dots high fluorescent signal amplification immunoassay using branched DNA and peptide nucleic acid conjugated antibody. *Analyst* (2011).
8. Chae B. J., *et al.* Measurement of ER and PR status in breast cancer using the QuantiGene2.0 assay. *Pathology* **43**(3):248-53 (2011).
9. Crombez L., *et al.* A non-covalent peptide-based strategy for ex vivo and in vivo oligonucleotide delivery. *Methods Mol Biol* **764**:59-73 (2011).
10. Hinfray N. *et al.* Characterization of testicular expression of P450 17alpha-hydroxylase, 17,20-lyase in zebrafish and its perturbation by the pharmaceutical fungicide clotrimazole. *Gen Comp Endocrinol* (2011).
11. Kadota K., *et al.* Evaluating methods for ranking differentially expressed genes applied to MicroArray Quality Control data. *BMC Bioinformatics* **12**(1):227 (2011).
12. Lapierre J., *et al.* Potent and systematic RNAi mediated silencing with single oligonucleotide compounds. *Rna* **17**(6):1032-7 (2011).
13. Li M., *et al.* Mutant hypoxia inducible factor-1alpha improves angiogenesis and tissue perfusion in ischemic rabbit skeletal muscle. *Microvasc Res* **81**(1):26-33 (2011).
14. Liao L. H., *et al.* Single-nucleotide polymorphisms and haplotype of CYP2E1 gene associated with systemic lupus erythematosus in Chinese population. *Arthritis Res Ther* **13**(1):R11 (2011).
15. Lin Y. Z., *et al.* The pathogenic and vaccine strains of equine infectious anemia virus differentially induce cytokine and chemokine expression and apoptosis in macrophages. *Virus Res* (2011).
16. Lu B., *et al.* The role of the transcription factor SIM2 in prostate cancer. *PLoS ONE* **6**(12):e28837 (2011).
17. Lu H., *et al.* Nrf2 protects against 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-induced oxidative injury and steatohepatitis. *Toxicol Appl Pharmacol* (2011).
18. Martin S. E., *et al.* RNAi screening identifies TAK1 as a potential target for the enhanced efficacy of topoisomerase inhibitors. *Curr Cancer Drug Targets*(2011).
19. Mital J., *et al.* A role for the Src-family kinase Fyn in sphingolipid acquisition by chlamydiae. *Infect Immun* (2011).
20. Murray L. A., *et al.* TGF-beta driven lung fibrosis is macrophage dependent and blocked by Serum amyloid P. *Int J Biochem Cell Biol* **43**(1):154-62 (2011).
21. Polach K. J., *et al.* Delivery of siRNA to the Mouse Lung via a Functionalized Lipopolyamine. *Mol Ther* (2011).

QuantiGene® 2.0 Bibliography

22. Selvaduray K. R., *et al.* Palm tocotrienols decrease levels of pro-angiogenic markers in human umbilical vein endothelial cells (HUVEC) and murine mammary cancer cells. *Genes Nutr* (2011).
23. Torres J. Z., *et al.* The STARD9/Kif16a kinesin associates with mitotic microtubules and regulates spindle pole assembly. *Cell* **147**(6):1309-23 (2011).
24. Trabzuni D., *et al.* Quality control parameters on a large dataset of regionally-dissected human control brains for whole genome expression studies. *J Neurochem* (2011).
25. Voth D. E., *et al.* The Coxiella burnetii cryptic plasmid is enriched in genes encoding type IV secretion system substrates. *J Bacteriol* **193**(7):1493-503 (2011).
26. Zheng W., Chung L. M., Zhao H. Bias detection and correction in RNA-Sequencing data. *BMC Bioinformatics* **12**(1):290 (2011).

2010

1. Abbott C., *et al.* Mouse monoclonal antibodies against human c-Mpl and characterization for flow cytometry applications. *Hybridoma (Larchmt)* **29**(2):103-13 (2009).
2. Addepalli H., *et al.* Modulation of thermal stability can enhance the potency of siRNA. *Nucleic Acids Res* (2010).
3. Akashi M., *et al.* Noninvasive method for assessing the human circadian clock using hair follicle cells. *Proc Natl Acad Sci USA* **107**(35):15643-8 (2010).
4. Aleksunes L. M., *et al.* Nuclear factor erythroid 2-related factor 2 deletion impairs glucose tolerance and exacerbates hyperglycemia in type 1 diabetic mice. *J Pharmacol Exp Ther* **333**(1):140-51 (2010).
5. Alnouti Y., *et al.* Mechanisms of gender-specific regulation of mouse sulfotransferases (Sults). *Xenobiotica* (2010).
6. Berahovich R. D., *et al.* CXCR7 protein is not expressed on human or mouse leukocytes. *J Immunol* (2010).
7. Chen Q., *et al.* Lipophilic siRNAs mediate efficient gene silencing in oligodendrocytes with direct CNS delivery. *J Control Release* (2010).
8. Chen Z., *et al.* Validation of the biotic ligand model in metal mixtures: bioaccumulation of lead and copper. *Environ Sci Technol* **44**(9):3580-6 (2010).
9. Cheneval D., *et al.* A review of methods to monitor the modulation of mRNA stability: a novel approach to drug discovery and therapeutic intervention. *J Biomol Screen* **15**(6):609-22 (2010).
10. Cui J. Y., *et al.* Genetic and epigenetic regulation and expression signatures of glutathione S-transferases in developing mouse liver. *Toxicol Sci* (2010).
11. Cui J. Y., *et al.* ChIPing the cistrome of PXR in mouse liver. *Nucleic Acids Res* (2010).
12. Debruin C., *et al.* Most purported antibodies to the human granulocyte colony-stimulating factor receptor are not specific. *Exp Hematol* (2010).

QuantiGene® 2.0 Bibliography

13. Ehsani A., et al. Rational design of micro-RNA-like bifunctional siRNAs targeting HIV and the HIV coreceptor CCR5. *Mol Ther* **18**(4):796-802 (2010).
14. Erickson H. S., et al. High throughput screening of normal and neoplastic tissue samples. *Comb Chem High Throughput Screen* **13**(3):253-67 (2010).
15. Furusato B., et al. ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification. *Prostate Cancer Prostatic Dis* **13**(3):228-37 (2010).
16. Genter M. B., et al. Drug transporter expression and localization in rat nasal respiratory and olfactory mucosa and olfactory bulb. *Drug Metab Dispos* **38**(10):1644-7 (2010).
17. Haobin W., et al. Detection and clinical significance of CEA,GCC and CD44v6 mRNA in peritoneal lavages of colorectal cancer patients:report of 60 cases. *Acta Academiae Medicinae Militaris Tertiae* **32**(1):36-40 (2010).
18. Hardwick R. N., et al. Diversity in antioxidant response enzymes in progressive stages of human nonalcoholic fatty liver disease. *Drug Metab Dispos* (2010).
19. Ibarra J. A., et al. Induction of Salmonella pathogenicity island 1 under different growth conditions can affect Salmonella-host cell interactions in vitro. *Microbiology* **156**(Pt 4):1120-33 (2010).
20. Jeong I., et al. Role of ataxia telangiectasia mutated in insulin signalling of muscle-derived cell lines and mouse soleus. *Acta Physiol (Oxf)* **198**(4):465-75 (2010).
21. Kaizerman J. A., et al. Addressing PXR liabilities of phthalazine-based hedgehog/smoothened antagonists using novel pyridopyridazines. *Bioorg Med Chem Lett* **20**(15):4607-10 (2010).
22. Lachaud A. A., et al. Werner's syndrome helicase participates in transcription of phenobarbital-inducible CYP2B genes in rat and mouse liver. *Biochem Pharmacol* **79**(3):463-70 (2010).
23. Love K. T., et al. Lipid-like materials for low-dose, in vivo gene silencing. *Proc Natl Acad Sci USA* (2010).
24. Lucas B. S., et al. Design of 1-piperazinyl-4-arylphthalazines as potent Smoothened antagonists. *Bioorg Med Chem Lett* **20**(12):3618-22 (2010).
25. Monovich L., et al. A novel kinase inhibitor establishes a predominant role for protein kinase D as a cardiac class IIa histone deacetylase kinase. *FEBS Lett* **584**(3):631-7 (2010).
26. Murray L. A., et al. Serum amyloid P therapeutically attenuates murine bleomycin-induced pulmonary fibrosis via its effects on macrophages. *PLoS One* **5**(3):e9683 (2010).
27. Musunuru K., et al. From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus. *Nature* **466**(7307):714-9 (2010).
28. Radaelli A., et al. Fowlpox virus recombinants expressing HPV-16 E6 and E7 oncogenes for the therapy of cervical carcinoma elicit humoral and cell-mediated responses in rabbits. *J Transl Med* **8**:40 (2010).

QuantiGene® 2.0 Bibliography

29. Robertson B., *et al.* Specificity and functionality of microRNA inhibitors. *Silence* **1**(1):10 (2010).
30. Salomon W., *et al.* Modified dsRNAs that are not processed by Dicer maintain potency and are incorporated into the RISC. *Nucleic Acids Res* (2010).
31. Sasu B. J., *et al.* Antihepcidin antibody treatment modulates iron metabolism and is effective in a mouse model of inflammation-induced anemia. *Blood* **115**(17):3616-24 (2010).
32. Semple S. C., *et al.* Rational design of cationic lipids for siRNA delivery. *Nat Biotechnol* (2010).
33. Srivastava S., *et al.* A two-parameter generalized Poisson model to improve the analysis of RNA-seq data. *Nucleic Acids Res* **38**(17):e170 (2010).
34. Stevens A., *et al.* Epigenetic changes in the hypothalamic proopiomelanocortin and glucocorticoid receptor genes in the ovine fetus after periconceptual undernutrition. *Endocrinology* **151**(8):3652-64 (2010).
35. Swift S., *et al.* Absence of functional EpoR expression in human tumor cell lines. *Blood* **115**(21):4254-63 (2010).
36. Talbot D. C., *et al.* Tumor survivin is downregulated by the antisense oligonucleotide LY2181308: a proof-of-concept, first-in-human dose study. *Clin Cancer Res* **16**(24):6150-8 (2010).
37. Wang L., *et al.* In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies. *Drug Metab Dispos* **38**(3):448-58 (2010).
38. Yim H. W., *et al.* Branched- chain Assay for ER, PR, and HER2 RNA Levels is a Useful Adjunct in the Evaluation of ER, PR, and HER2 in Breast Cancer. *J Breast Cancer* **13**(3):267-74 (2010).
39. Yue X., *et al.* Transcriptional regulation by small RNAs at sequences downstream from 3' gene termini. *Nat Chem Biol* **6**(8):621-9 (2010).
40. Zhang L., *et al.* A new biosimetric method: branched DNA-based quantitative detection of B1 DNA in mouse plasma. *Br J Radiol* **83**(992):694-701 (2010).
41. Zhang Y. K., *et al.* Enhanced expression of Nrf2 in mice attenuates the fatty liver produced by a methionine- and choline-deficient diet. *Toxicol Appl Pharmacol* **245**(3):326-34 (2010).
42. Zumbansen M., *et al.* First siRNA library screening in hard-to-transfect HUVEC cells. *J RNAi Gene Silencing* **6**(1):354-60 (2010).

2009

1. Beetz N., *et al.* Phosducin influences sympathetic activity and prevents stress-induced hypertension in humans and mice. *J Clin Invest* **119**(12):3597-612 (2009).
2. Berrodin T. J., *et al.* Novel progesterone receptor modulators with gene selective and context-dependent partial agonism. *Biochem Pharmacol* **77**(2):204-15 (2009).

QuantiGene® 2.0 Bibliography

3. Buckley D. B., Klaassen C. D. Induction of mouse UDP-glucuronosyltransferase mRNA expression in liver and intestine by activators of aryl-hydrocarbon receptor, constitutive androstane receptor, pregnane X receptor, peroxisome proliferator-activated receptor alpha, and nuclear factor erythroid 2-related factor 2. *Drug Metab Dispos* **37**(4):847-56 (2009).
4. Buckley D. B., Klaassen C. D. Mechanism of gender-divergent UDP-glucuronosyltransferase mRNA expression in mouse liver and kidney. *Drug Metab Dispos* **37**(4):834-40 (2009).
5. Champion S. N., et al. Effect of allyl alcohol on hepatic transporter expression: Zonal patterns of expression and role of Kupffer cell function. *Toxicology and Applied Pharmacology* **236**:49–58 (2009).
6. Chapuis J., et al. Transcriptomic and genetic studies identify IL-33 as a candidate gene for Alzheimer's disease. *Mol Psychiatry* **14**(11):1004-16 (2009).
7. Cheng X., Klaassen C. D. Tissue distribution, ontogeny, and hormonal regulation of xenobiotic transporters in mouse kidneys. *Drug Metab Dispos* **37**(11):2178-85 (2009).
8. Cui Y. J., et al. Tissue distribution, gender-divergent expression, ontogeny, and chemical induction of multidrug resistance transporter genes (Mdr1a, Mdr1b, Mdr2) in mice. *Drug Metab Dispos* **37**(1):203-10 (2009).
9. Cui Y. J., et al. Ontogenic expression of hepatic Ahr mRNA is associated with histone H3K4 di-methylation during mouse liver development. *Toxicol Lett* **189**(3):184-90 (2009).
10. Ellison D. W., et al. Limited transcriptional responses of Rickettsia rickettsii exposed to environmental stimuli. *PLoS One* **4**(5):e5612 (2009).
11. Fortin M., et al. A multi-target antisense approach against PDE4 and PDE7 reduces smoke-induced lung inflammation in mice. *Respir Res* **10**:39 (2009).
12. Grunt T. W., et al. Interaction between fatty acid synthase- and ErbB-systems in ovarian cancer cells. *Biochem Biophys Res Commun* **385**(3):454-9 (2009).
13. Haag J., et al. Efficient non-viral transfection of primary human adult chondrocytes in a high-throughput format. *Osteoarthritis Cartilage* **17**(6):813-7 (2009).
14. Kanashiro-Takeuchi R. M., et al. Sex-Specific Impact of Aldosterone Receptor Antagonism on Ventricular Remodeling and Gene Expression after Myocardial Infarction. *Clin Transl Sci* **2**(2):134-42 (2009).
15. Kwara A., et al. Interindividual Variability in Pharmacokinetics of Generic Nucleoside Reverse Transcriptase Inhibitors in TB/HIV-Coinfected Ghanaian Patients: UGT2B7*1c Is Associated With Faster Zidovudine Clearance and Glucuronidation. *J Clin Pharmacol* **49**(9):1079-90 (2009).
16. Lu B., et al. Detection of TMPRSS2-ERG fusion gene expression in prostate cancer specimens by a novel assay using branched DNA. *Urology* **74**(5):1156-61 (2009).
17. Mahmoudi S., et al. Wrap53, a natural p53 antisense transcript required for p53 induction upon DNA damage. *Mol Cell* **33**(4):462-71 (2009).

QuantiGene® 2.0 Bibliography

18. Mane S. P., *et al.* Transcriptome sequencing of the Microarray Quality Control (MAQC) RNA reference samples using next generation sequencing. *BMC Genomics* **10**(1):264 (2009).
19. Passioura T., *et al.* Interfering ribonucleic acids that suppress expression of multiple unrelated genes. *BMC Biotechnol* **9**(1):57 (2009).
20. Shinonaga H., *et al.* Pochonins K–P: new radicicol analogues from *Pochonia chlamydosporia* var. *chlamydosporia* and their WNT-5A expression inhibitory activities. *Tetrahedron* **65**:3446–53 (2009).
21. Shinonaga H., *et al.* Synthesis and structure-activity relationships of radicicol derivatives and WNT-5A expression inhibitory activity. *Bioorg Med Chem* **17**(13):4622-35 (2009).
22. Shinonaga H., *et al.* The search for a hair-growth stimulant: new radicicol analogues as WNT-5A expression inhibitors from *Pochonia chlamydosporia* var. *chlamydosporia*. *Tetrahedron Letters* **50**:108-10 (2009).
23. Surguladze D., *et al.* Tumor necrosis factor-alpha and interleukin-1 antagonists alleviate inflammatory skin changes associated with epidermal growth factor receptor antibody therapy in mice. *Cancer Res* **69**(14):5643-7 (2009).
24. Tanaka Y., *et al.* ANIT-induced intrahepatic cholestasis alters hepatobiliary transporter expression via Nrf2-dependent and independent signaling. *Toxicol Sci* **108**(2):247-57 (2009).
25. Vickers A. E., Characterization of hepatic mitochondrial injury induced by fatty acid oxidation inhibitors. *Toxicol Pathol* **37**(1):78-88 (2009).
26. Zhu J., *et al.* Regulation of apolipoprotein AI (apoAI) processing by Procollagen C-proteinase enhancer (PCPE2) and bone morphogenetic protein-1 (BMP-1). *J Lipid Res* (2009).

2008

1. Aagaard L. A., *et al.* Engineering and optimization of the miR-106b cluster for ectopic expression of multiplexed anti-HIV RNAs. *Gene Ther* **15**(23):1536-49 (2008).
2. Akinc A., *et al.* A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. *Nat Biotechnol* **26**(5):561-9 (2008).
3. Aleksunes L. M., *et al.* Induction of Mrp3 and Mrp4 transporters during acetaminophen hepatotoxicity is dependent on Nrf2. *Toxicol Appl Pharmacol* **226**(1):74-83 (2008).
4. Aleksunes L. M., *et al.* Renal xenobiotic transporters are differentially expressed in mice following cisplatin treatment. *Toxicology* **250**(2-3):82-8 (2008).
5. Aleksunes L. M., Cui Y., Klaassen C. D. Prominent expression of xenobiotic efflux transporters in mouse extraembryonic fetal membranes compared with placenta. *Drug Metab Dispos* (2008).
6. Aleku M., *et al.* Atu027, a liposomal small interfering RNA formulation targeting protein kinase N3, inhibits cancer progression. *Cancer Res* **68**(23):9788-98 (2008).

QuantiGene® 2.0 Bibliography

7. Alnouti Y., Klaassen C. D. Regulation of sulfotransferase enzymes by prototypical microsomal enzyme inducers in mice. *J Pharmacol Exp Ther* **324**(2):612-21 (2008).
8. Alnouti Y., Klaassen C. D. Tissue distribution, ontogeny, and regulation of aldehyde dehydrogenase (aldh) enzymes mRNA by prototypical microsomal enzyme inducers in mice. *Toxicol Sci* **101**(1):51-64 (2008).
9. Anderson E., et al. Identifying siRNA-induced off-targets by microarray analysis. *Methods Mol Biol* **442**:45-63 (2008).
10. Anderson E. M., et al. Experimental validation of the importance of seed complement frequency to siRNA specificity. *Rna* **14**(5):853-61 (2008).
11. Arikawa E., et al. Cross-platform comparison of SYBR Green real-time PCR with TaqMan PCR, microarrays and other gene expression measurement technologies evaluated in the MicroArray Quality Control (MAQC) study. *BMC Genomics* **9**:328 (2008).
12. Beilke L. D., et al. Minimal role of hepatic transporters in the hepatoprotection against LCA-induced intrahepatic cholestasis. *Toxicol Sci* **102**(1):196-204 (2008).
13. Calcagno A. M., et al. Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes. *Br J Cancer* **98**(9):1515-24 (2008).
14. Chae Y. K., et al. Human AQP5 plays a role in the progression of chronic myelogenous leukemia (CML). *PLoS ONE* **3**(7):e2594 (2008).
15. Cheng Q., et al. Drug-metabolizing enzyme and transporter expression in a mouse model of diabetes and obesity. *Mol Pharm* **5**(1):77-91 (2008).
16. Cheng X., Klaassen C. D. Perfluorocarboxylic acids induce cytochrome P450 enzymes in mouse liver through activation of PPAR-alpha and CAR transcription factors. *Toxicol Sci* **106**(1):29-36 (2008).
17. Cheng X. Klaassen C. D. Critical role of PPAR-alpha in perfluorooctanoic acid- and perfluorodecanoic acid-induced downregulation of Oatp uptake transporters in mouse livers. *Toxicol Sci* **106**(1):37-45 (2008).
18. Chung J. Y., et al. Factors in tissue handling and processing that impact RNA obtained from formalin-fixed, paraffin-embedded tissue. *J Histochem Cytochem* **56**(11):1033-42 (2008).
19. Crombez L., et al. A New Potent Secondary Amphipathic Cell-penetrating Peptide for siRNA Delivery Into Mammalian Cells. *Mol Ther* (2008).
20. Eastham L. L., Mills C. N., Niles R. M. PPARalpha/gamma Expression and Activity in Mouse and Human Melanocytes and Melanoma Cells. *Pharm Res* (2008).
21. Fisher C. D., et al. Drug metabolizing enzyme induction pathways in experimental non-alcoholic steatohepatitis. *Arch Toxicol* **82**(12):959-64 (2008).
22. Frank-Kamenetsky M., et al. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. *Proc Natl Acad Sci U S A* (2008).

QuantiGene® 2.0 Bibliography

23. Grueneberg D. A., *et al.* Kinase requirements in human cells: IV. Differential kinase requirements in cervical and renal human tumor cell lines. *Proc Natl Acad Sci U S A* **105**(43):16490-5 (2008).
24. Gyamfi M. A., *et al.* Hepatic effects of a methionine-choline-deficient diet in hepatocyte RXRalpha-null mice. *Toxicol Appl Pharmacol* (2008).
25. Hart S. N., *et al.* Genetic polymorphisms in cytochrome P450 oxidoreductase influence microsomal P450-catalyzed drug metabolism. *Pharmacogenet Genomics* **18**(1):11-24 (2008).
26. Halpern M. D., Dvorak B. Does Abnormal Bile Acid Metabolism Contribute to NEC? *Semin Perinatol* **32**(2):114-21 (2008).
27. Honda M., *et al.* Specific knockdown of m-calpain blocks myogenesis with cDNA deduced from the corresponding RNAi. *Am J Physiol Cell Physiol* (2008).
28. Hubbard K., *et al.* Knockdown of TFIIS by RNA silencing inhibits cancer cell proliferation and induces apoptosis. *BMC Cancer* **8**:133 (2008).
29. Jonson A. L., *et al.* Gene silencing with siRNA targeting E6/E7 as a therapeutic intervention in a mouse model of cervical cancer. *Gynecol Oncol* (2008).
30. Knight T. R., Choudhuri S., Klaassen C. D. Induction of hepatic glutathione S-transferases in male mice by prototypes of various classes of microsomal enzyme inducers. *Toxicol Sci* **106**(2):329-38 (2008).
31. Knudsen B. S., *et al.* Evaluation of the branched-chain DNA assay for measurement of RNA in formalin-fixed tissues. *J Mol Diagn* (2008).
32. Lee A. C., *et al.* Electrochemical branched-DNA assay for polymerase chain reaction-free detection and quantification of oncogenes in messenger RNA. *Anal Chem* (2008).
33. Lickteig A. J., *et al.* Tissue distribution, ontogeny and induction of the transporters Multidrug and toxin extrusion (MATE) 1 and MATE2 mRNA expression levels in mice. *Life Sci* **83**(1-2):59-64 (2008).
34. Lorenzi P. L., *et al.* Asparagine synthetase is a predictive biomarker of L-asparaginase activity in ovarian cancer cell lines. *Mol Cancer Ther* **7**(10):3123-8 (2008).
35. Lu H., Klaassen C. Gender differences in mRNA expression of ATP-binding cassette efflux and bile acid transporters in kidney, liver, and intestine of 5/6 nephrectomized rats. *Drug Metab Dispos* **36**(1):16-23 (2008).
36. Lu H., *et al.* Characterization of organic anion transporting polypeptide 1b2-null mice: essential role in hepatic uptake/toxicity of phalloidin and microcystin-LR. *Toxicol Sci* (2008).
37. Maher J. M., *et al.* Nrf2- and PPAR alpha-mediated regulation of hepatic Mrp transporters after exposure to perfluorooctanoic acid and perfluorodecanoic acid. *Toxicol Sci* **106**(2):319-28 (2008).
38. Merrell M. D., *et al.* The Nrf2 activator oltipraz also activates the constitutive androstane receptor. *Drug Metab Dispos* **36**(8):1716-21 (2008).

QuantiGene® 2.0 Bibliography

39. Migliaccio C. T., *et al.* The IL-4Ralpha pathway in macrophages and its potential role in silica-induced pulmonary fibrosis. *J Leukoc Biol* **83**(3):630-9 (2008).
40. Moore M., *et al.* Measurement of neutralising antibodies to type I interferons by gene expression assays specific for type 1 interferon-inducible 6-16 mRNA. *J Pharm Biomed Anal* (2008).
41. Nair A., *et al.* A rapid and efficient branched DNA hybridization assay to titer lentiviral vectors. *J Virol Methods* **153**(2):269-72 (2008).
42. Querbes W., *et al.* Direct CNS Delivery of siRNA Mediates Robust Silencing in Oligodendrocytes. *Oligonucleotides* (2008).
43. Robbins M., *et al.* Misinterpreting the therapeutic effects of small interfering RNA caused by immune stimulation. *Hum Gene Ther* (2008).
44. Ryan M. C., *et al.* SpliceCenter: a suite of web-based bioinformatic applications for evaluating the impact of alternative splicing on RT-PCR, RNAi, microarray, and peptide-based studies. *BMC Bioinformatics* **9**:313 (2008).
45. Sano M., *et al.* Expression of long anti-HIV-1 hairpin RNAs for the generation of multiple siRNAs: advantages and limitations. *Mol Ther* **16**(1):170-7 (2008).
46. Shou M., *et al.* Modeling, prediction, and in vitro in vivo correlation of CYP3A4 induction. *Drug Metab Dispos* **36**(11):2355-70 (2008).
47. Simpson K. J., *et al.* Identification of genes that regulate epithelial cell migration using an siRNA screening approach. *Nat Cell Biol* (2008).
48. Tanaka Y., *et al.* NF-E2-related factor 2 inhibits lipid accumulation and oxidative stress in mice fed a high-fat diet. *J Pharmacol Exp Ther* (2008).
49. Tanaka Y., *et al.* Coordinated induction of Nrf2 target genes protects against iron nitrilotriacetate (FeNTA)-induced nephrotoxicity. *Toxicol Appl Pharmacol* **231**(3):364-73 (2008).
50. Tanaka Y., *et al.* Ischemia-reperfusion of rat livers decreases liver and increases kidney multidrug resistance associated protein 2 (Mrp2). *Toxicol Sci* **101**(1):171-8 (2008).
51. Unwalla H. J., *et al.* Use of a U16 snoRNA-containing ribozyme library to identify ribozyme targets in HIV-1. *Mol Ther* **16**(6):1113-9 (2008).
52. Zhang Y. K., Yeager R. L., Klaassen C. D. Circadian expression profiles of drug-processing genes and transcription factors in mouse liver. *Drug Metab Dispos* (2008).
53. Zhou Y., *et al.* Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda6-benzo[1',2',4']thiadiazin-3'-yl)-5- hydroxy-2H-pyridazin-3-ones. Part 1: exploration of 7'-substitution of benzothiadiazine. *Bioorg Med Chem Lett* **18**(4):1413-8 (2008).

2007

1. Aleksunes L. M., *et al.* Influence of acetaminophen vehicle on regulation of transporter gene expression during hepatotoxicity. *J Toxicol Environ Health A* **70**(21):1870-2 (2007).

QuantiGene® 2.0 Bibliography

2. Barnes S. N., *et al.* Induction of hepatobiliary efflux transporters in acetaminophen-induced acute liver failure cases. *Drug Metab Dispos* **35**(10):1963-9 (2007).
3. Buckley D. B., Klaassen C. D. Tissue- and gender-specific mRNA expression of UDP-glucuronosyltransferases (UGTs) in mice. *Drug Metab Dispos* **35**(1):121-7 (2007).
4. Chen C., *et al.* Activation of cAMP-dependent signaling pathway induces mouse organic anion transporting polypeptide 2 expression. *Mol Pharmacol* **71**(4):1159-64 (2007).
5. Cheng X., *et al.* Regulation of hepatic bile acid transporters Ntcp and Bsep expression. *Biochem Pharmacol* **74**(11):1665-76 (2007).
6. Cheshenko K., *et al.* Expression of zebra fish aromatase cyp19a and cyp19b genes in response to the ligands of estrogen receptor and aryl hydrocarbon receptor. *Toxicol Sci* **96**(2):255-67 (2007).
7. Coates S. S., *et al.* Beryllium induces premature senescence in human fibroblasts. *J Pharmacol Exp Ther* **322**(1):70-9 (2007).
8. Dotzlaw J., *et al.* Derivation and characterization of monoclonal antibodies against human folypolyglutamate synthetase. *Hybridoma (Larchmt)* **26**(3):155-61 (2007).
9. Fisher C. D., *et al.* Induction of drug-metabolizing enzymes by garlic and allyl sulfide compounds via activation of constitutive androstane receptor and nuclear factor E2-related factor 2. *Drug Metab Dispos* **35**(6):995-1000 (2007).
10. Hernandez S., Chavez Munguia B., Gonzalez-Mariscal L. ZO-2 silencing in epithelial cells perturbs the gate and fence function of tight junctions and leads to an atypical monolayer architecture. *Exp Cell Res* **313**(8):1533-47 (2007).
11. John M., *et al.* Effective RNAi-mediated gene silencing without interruption of the endogenous microRNA pathway. *Nature* **449**(7163):745-7 (2007).
12. Knight T. R., Choudhuri S., Klaassen C. D. Constitutive mRNA expression of various glutathione s-transferase isoforms in different tissues of mice. *Toxicol Sci* **100**(2):513-24 (2007).
13. Lantz R. C., *et al.* The effect of extracts from ginger rhizome on inflammatory mediator production. *Phytomedicine* **14**(2-3):123-8 (2007).
14. Lickteig A. J., *et al.* Genes of the antioxidant response undergo upregulation in a rodent model of nonalcoholic steatohepatitis. *J Biochem Mol Toxicol* **21**(4):216-20 (2007).
15. Lickteig A. J., *et al.* Efflux transporter expression and acetaminophen metabolite excretion are altered in rodent models of nonalcoholic fatty liver disease. *Drug Metab Dispos* **35**(10):1970-8 (2007).
16. Lickteig A. J., *et al.* Differential regulation of hepatic transporters in the absence of tumor necrosis factor-alpha, interleukin-1beta, interleukin-6, and nuclear factor-kappaB in two models of cholestasis. *Drug Metab Dispos* **35**(3):402-9 (2007).
17. Lin X., *et al.* 'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737. *Oncogene* **26**(27):3972-9 (2007).

QuantiGene® 2.0 Bibliography

18. Martin S. E., *et al.* Multiplexing siRNAs to compress RNAi-based screen size in human cells. *Nucleic Acids Res* (2007).
19. Miao Z., *et al.* CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature. *Proc Natl Acad Sci U S A* **104**(40):15735-40 (2007).
20. Miao Z. H., *et al.* Nonclassic functions of human topoisomerase I: genome-wide and pharmacologic analyses. *Cancer Res* **67**(18):8752-61 (2007).
21. Pacyniak E. K., *et al.* The flame retardants, polybrominated diphenyl ethers, are pregnane X receptor activators. *Toxicol Sci* (2007).
22. Petrick J. S., Klaassen C. D. Importance of hepatic induction of constitutive androstane receptor and other transcription factors that regulate xenobiotic metabolism and transport. *Drug Metab Dispos* **35**(10):1806-15 (2007).
23. Slitt A. L., *et al.* Regulation of transporter expression in mouse liver, kidney, and intestine during extrahepatic cholestasis. *Biochim Biophys Acta* **1768**(3):637-47 (2007).
24. Tanaka Y., *et al.* Hepatic ischemia-reperfusion induces renal heme oxygenase-1 via NF-E2-related factor 2 in rats and mice. *Mol Pharmacol* **71**(3):817-25 (2007).
25. Vermeulen A., *et al.* Double-stranded regions are essential design components of potent inhibitors of RISC function. *RNA* **13**(5):723-30 (2007).
26. Wei X., *et al.* Development and validation of a quantitative cell-based bioassay for comparing the pharmacokinetic profiles of two recombinant erythropoietic proteins in serum. *J Pharm Biomed Anal* **43**(2):666-76 (2007).
27. Wen X., Walle T. Cytochrome P450 1B1, a novel chemopreventive target for benzo[a]pyrene-initiated human esophageal cancer. *Cancer Lett* **246**(1-2):109-14 (2007).
28. Wolfrum C., *et al.* Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. *Nat Biotechnol* **25**(10):1149-57 (2007).
29. Yamaguchi T., *et al.* Identification of JTP-70902, a p15(INK4b)-inductive compound, as a novel MEK1/2 inhibitor. *Cancer Sci* **98**(11):1809-16 (2007).
30. Yuan Q., *et al.* Age-dependent expression of the cystatin-related epididymal spermatogenic (Cres) gene in mouse testis and epididymis. *Asian J Androl* **9**(3):305-11 (2007).
31. Zhang X., Cherrington N. J., Wright S. H. Molecular identification and functional characterization of rabbit MATE1 and MATE2-K. *Am J Physiol Renal Physiol* **293**(1):F360-70 (2007).
32. Zhou Y., *et al.* Phenotypic and structural analyses of hepatitis C virus NS3 protease Arg155 variants: sensitivity to telaprevir (VX-950) and interferon alpha. *J Biol Chem* **282**(31):22619-28 (2007).

QuantiGene® 2.0 Bibliography

2006

1. Aleksunes L. M., *et al.* Nuclear factor-E2-related factor 2 expression in liver is critical for induction of NAD(P)H:quinone oxidoreductase 1 during cholestasis. *Cell Stress Chaperones* **11**(4):356-63 (2006).
2. Alnouti Y., Klaassen C. D. Tissue distribution and ontogeny of sulfotransferase enzymes in mice. *Toxicol Sci* **93**(2):242-55 (2006).
3. Alnouti Y., Petrick J. S., Klaassen C. D. Tissue distribution and ontogeny of organic cation transporters in mice. *Drug Metab Dispos* **34**(3):477-82 (2006).
4. Canales R. D., *et al.* Evaluation of DNA microarray results with quantitative gene expression platforms. *Nat Biotechnol* **24**(9):1115-22 (2006).
5. Cheng X., Klaassen C. D. Regulation of mRNA expression of xenobiotic transporters by the pregnane x receptor in mouse liver, kidney, and intestine. *Drug Metab Dispos* **34**(11):1863-7 (2006).
6. Cheng X., *et al.* Endocrine regulation of gender-divergent mouse organic anion-transporting polypeptide (Oatp) expression. *Mol Pharmacol* **70**(4):1291-7 (2006).
7. Conrad P. G., Chavli R. V., Givens R. S. Caged substrates applied to high content screening: an introduction with an eye to the future. *Methods Mol Biol* **356**:253-66 (2006).
8. Das P. C., *et al.* Fipronil induces CYP isoforms and cytotoxicity in human hepatocytes. *Chem Biol Interact* **164**(3):200-14 (2006).
9. Deng D. X., *et al.* Differences in vascular bed disease susceptibility reflect differences in gene expression response to atherogenic stimuli. *Circ Res* **98**(2):200-8 (2006).
10. Dotzlaw J., *et al.* Derivation and characterization of a monoclonal antibody against human glycinamide ribonucleotide formyltransferase. *Hybridoma (Larchmt)* **25**(3):139-44 (2006).
11. Fedorov Y., *et al.* Off-target effects by siRNA can induce toxic phenotype. *RNA* **12**(7):1188-96 (2006).
12. Ferrari N., *et al.* Characterization of antisense oligonucleotides comprising 2'-deoxy-2'-fluoro-beta-D-arabinonucleic acid (FANA): specificity, potency, and duration of activity. *Ann N Y Acad Sci* **1082**:91-102 (2006).
13. Fortin M., *et al.* Effects of antisense oligodeoxynucleotides targeting CCR3 on the airway response to antigen in rats. *Oligonucleotides* **16**(3):203-12 (2006).
14. Groves C. E., *et al.* Sex differences in the mRNA, protein, and functional expression of organic anion transporter (Oat) 1, Oat3, and organic cation transporter (Oct) 2 in rabbit renal proximal tubules. *J Pharmacol Exp Ther* **316**(2):743-52 (2006).
15. Hinfray N., *et al.* Brain and gonadal aromatase as potential targets of endocrine disrupting chemicals in a model species, the zebrafish (Danio rerio). *Environ Toxicol* **21**(4):332-7 (2006).
16. Judge A. D., *et al.* Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. *Mol Ther* **13**(3):494-505 (2006).

QuantiGene® 2.0 Bibliography

17. Kolachala V. L., *et al.* Adenosine 2b receptor (A2bR) signals through adenylate cyclase (AC) 6 isoform in the intestinal epithelial cells. *Biochim Biophys Acta* **1760**(7):1102-8 (2006).
18. Laville N., *et al.* Modulation of aromatase activity and mRNA by various selected pesticides in the human choriocarcinoma JEG-3 cell line. *Toxicology* **228**(1):98-108 (2006).
19. Lin X., *et al.* 'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-X(L) inhibitor ABT-737. *Oncogene* (2006).
20. Lorenzi P. L., *et al.* Asparagine synthetase as a causal, predictive biomarker for L-asparaginase activity in ovarian cancer cells. *Mol Cancer Ther* **5**(11):2613-23 (2006).
21. Lu H., Lei X., Klaassen C. Gender differences in renal nuclear receptors and aryl hydrocarbon receptor in 5/6 nephrectomized rats. *Kidney Int* **70**(11):1920-8 (2006).
22. Maher J. M., *et al.* Alterations in transporter expression in liver, kidney, and duodenum after targeted disruption of the transcription factor HNF1alpha. *Biochem Pharmacol* **72**(4):512-22 (2006).
23. Maher J. M., *et al.* Hormonal regulation of renal multidrug resistance-associated proteins 3 and 4 (Mrp3 and Mrp4) in mice. *Biochem Pharmacol* **71**(10):1470-8 (2006).
24. Majercak J., *et al.* LRRTM3 promotes processing of amyloid-precursor protein by BACE1 and is a positional candidate gene for late-onset Alzheimer's disease. *Proc Natl Acad Sci U S A* **103**(47):17967-72 (2006).
25. Moffit J. S., *et al.* Induction of hepatic transporters multidrug resistance-associated proteins (Mrp) 3 and 4 by clofibrate is regulated by peroxisome proliferator-activated receptor alpha. *J Pharmacol Exp Ther* **317**(2):537-45 (2006).
26. Nguyen Q. N., *et al.* Light controllable siRNAs regulate gene suppression and phenotypes in cells. *Biochim Biophys Acta* **1758**(3):394-403 (2006).
27. Nishiu J., *et al.* JTP-426467 acts as a selective antagonist for peroxisome proliferator-activated receptor gamma in vitro and in vivo. *Diabetes Obes Metab* **8**(5):508-16 (2006).
28. Pruijboom-Brees I., *et al.* A critical role for peroxisomal proliferator-activated receptor-alpha nuclear receptors in the development of cardiomyocyte degeneration and necrosis. *Am J Pathol* **169**(3):750-60 (2006).
29. Reynolds A., *et al.* Induction of the interferon response by siRNA is cell type- and duplex length-dependent. *RNA* **12**(6):988-93 (2006).
30. Saetrom P., *et al.* Conserved microRNA characteristics in mammals. *Oligonucleotides* **16**(2):115-44 (2006).
31. Schmidt R. J., *et al.* A 15-ketosterol is a liver X receptor ligand that suppresses sterol-responsive element binding protein-2 activity. *J Lipid Res* **47**(5):1037-44 (2006).
32. Shelby M. K., Klaassen C. D. Induction of rat UDP-glucuronosyltransferases in liver and duodenum by microsomal enzyme inducers that activate various transcriptional pathways. *Drug Metab Dispos* **34**(10):1772-8 (2006).

QuantiGene® 2.0 Bibliography

33. Shi L., *et al.* The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. *Nat Biotechnol* **24**(9):1151-61 (2006).
34. Slitt A. L., *et al.* trans-Stilbene oxide induces expression of genes involved in metabolism and transport in mouse liver via CAR and Nrf2 transcription factors. *Mol Pharmacol* **69**(5):1554-63 (2006).
35. Slitt A. L., *et al.* Induction of genes for metabolism and transport by trans-stilbene oxide in livers of Sprague-Dawley and Wistar-Kyoto rats. *Drug Metab Dispos* **34**(7):1190-7 (2006).
36. Stanley L. A., *et al.* PXR and CAR: nuclear receptors which play a pivotal role in drug disposition and chemical toxicity. *Drug Metab Rev* **38**(3):515-97 (2006).
37. Tanaka Y., *et al.* Kupffer cell-mediated downregulation of hepatic transporter expression in rat hepatic ischemia-reperfusion. *Transplantation* **82**(2):258-66 (2006).
38. Tsuji P. A., Walle T. Inhibition of benzo[a]pyrene-activating enzymes and DNA binding in human bronchial epithelial BEAS-2B cells by methoxylated flavonoids. *Carcinogenesis* **27**(8):1579-85 (2006).
39. Yang W., *et al.* Direct quantification of gene expression in homogenates of formalin-fixed, paraffin-embedded tissues. *Biotechniques* **40**(4):481-6 (2006).
40. Yu M., Yeh J., Van Waes C. Protein kinase casein kinase 2 mediates inhibitor-kappaB kinase and aberrant nuclear factor-kappaB activation by serum factor(s) in head and neck squamous carcinoma cells. *Cancer Res* **66**(13):6722-31 (2006).
41. Yu Y., *et al.* A novel method for detecting neutralizing antibodies against therapeutic proteins by measuring gene expression. *J Immunol Methods* **316**(1-2):8-17 (2006).
42. Yudit M. R., *et al.* Selective and opposing actions of progesterone receptor isoforms in human endometrial stromal cells. *Mol Cell Endocrinol* **247**(1-2):116-26 (2006).
43. Zheng Z., Luo Y., McMaster G. K. Sensitive and quantitative measurement of gene expression directly from a small amount of whole blood. *Clin Chem* **52**(7):1294-302 (2006).
44. Zimmermann T. S., *et al.* RNAi-mediated gene silencing in non-human primates. *Nature* **441**(7089):111-4 (2006).

2005

1. Aleksunes L. M., *et al.* Differential expression of mouse hepatic transporter genes in response to acetaminophen and carbon tetrachloride. *Toxicol Sci* **83**(1):44-52 (2005).
2. Alikhani M., Alikhani Z., Graves D. T. FOXO1 functions as a master switch that regulates gene expression necessary for tumor necrosis factor-induced fibroblast apoptosis. *J Biol Chem* **280**(13):12096-102 (2005).
3. Augustine L. M., *et al.* Xenobiotic and endobiotic transporter mRNA expression in the blood-testis barrier. *Drug Metab Dispos* **33**(1):182-9 (2005).

QuantiGene® 2.0 Bibliography

4. Burris T. P., *et al.* The hypolipidemic natural product guggulsterone is a promiscuous steroid receptor ligand. *Mol Pharmacol* **67**(3):948-54 (2005).
5. Cheng X., *et al.* Tissue distribution and ontogeny of mouse organic anion transporting polypeptides (Oatps). *Drug Metab Dispos* **33**(7):1062-73 (2005).
6. Cheng X., *et al.* Regulation of mouse organic anion-transporting polypeptides (Oatps) in liver by prototypical microsomal enzyme inducers that activate distinct transcription factor pathways. *Drug Metab Dispos* **33**(9):1276-82 (2005).
7. Croutch C. R., *et al.* 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) and 1,2,3,4,7,8-hexachlorodibenzo-p-dioxin (HxCDD) alter body weight by decreasing insulin-like growth factor I (IGF-I) signaling. *Toxicol Sci* **85**(1):560-71 (2005).
8. Dai G., *et al.* Retinoid X receptor alpha Regulates the expression of glutathione s-transferase genes and modulates acetaminophen-glutathione conjugation in mouse liver. *Mol Pharmacol* **68**(6):1590-6 (2005).
9. Erickson R. P., *et al.* Liver disease with altered bile acid transport in Niemann-Pick C mice on a high-fat, 1% cholesterol diet. *Am J Physiol Gastrointest Liver Physiol* **289**(2):G300-7 (2005).
10. Gruber J., *et al.* RNAi of FACE1 protease results in growth inhibition of human cells expressing lamin A: implications for Hutchinson-Gilford progeria syndrome. *J Cell Sci* **118**(Pt 4):689-96 (2005).
11. Kolachala V., *et al.* TNF-alpha upregulates adenosine 2b (A2b) receptor expression and signaling in intestinal epithelial cells: a basis for A2bR overexpression in colitis. *Cell Mol Life Sci* **62**(22):2647-57 (2005).
12. Krishnan V., *et al.* The nongenotropic synthetic ligand 4-estren-3alpha17beta-diol is a high-affinity genotropic androgen receptor agonist. *Mol Pharmacol* **67**(3):744-8 (2005).
13. Krishnaswamy S., *et al.* UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetics: I. Identification of polymorphisms in the 5'-regulatory and exon 1 regions, and association with human liver UGT1A6 gene expression and glucuronidation. *J Pharmacol Exp Ther* **313**(3):1331-9 (2005).
14. Li N., Klaassen C. D. Lipopolysaccharide-induced down-regulation of organic anion transporting polypeptide 4 (Oatp4; Slc21a10) is independent of tumor necrosis factor-alpha, Interleukin-1beta, interleukin-6, or inducible nitric oxide synthase. *Toxicol Sci* **83**(1):197-203 (2005).
15. Maher J. M., *et al.* Induction of the multidrug resistance-associated protein family of transporters by chemical activators of receptor-mediated pathways in mouse liver. *Drug Metab Dispos* **33**(7):956-62 (2005).
16. Maher J. M., *et al.* Tissue distribution and hepatic and renal ontogeny of the multidrug resistance-associated protein (Mrp) family in mice. *Drug Metab Dispos* **33**(7):947-55 (2005).
17. Sawada H., Takami K., Asahi S. A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system. *Toxicol Sci* **83**(2):282-92 (2005).

QuantiGene® 2.0 Bibliography

18. Silva V. M., *et al.* Transport deficient (TR-) hyperbilirubinemic rats are resistant to acetaminophen hepatotoxicity. *Biochem Pharmacol* **70**(12):1832-9 (2005).
19. Stayrook K. R., *et al.* Regulation of carbohydrate metabolism by the farnesoid X receptor. *Endocrinology* **146**(3):984-91 (2005).
20. Thukral S. K., *et al.* Prediction of nephrotoxicant action and identification of candidate toxicity-related biomarkers. *Toxicol Pathol* **33**(3):343-55 (2005).
21. Vermeulen A., *et al.* The contributions of dsRNA structure to Dicer specificity and efficiency. *Rna* **11**(5):674-82 (2005).
22. Wen X., Walle T. Preferential induction of CYP1B1 by benzo[a]pyrene in human oral epithelial cells: impact on DNA adduct formation and prevention by polyphenols. *Carcinogenesis* **26**(10):1774-81 (2005).
23. Wen X., Walle U. K., Walle T. 5,7-Dimethoxyflavone downregulates CYP1A1 expression and benzo[a]pyrene-induced DNA binding in Hep G2 cells. *Carcinogenesis* **26**(4):803-9 (2005).

2004

1. Buist S. C., Klaassen C. D. Rat and mouse differences in gender-predominant expression of organic anion transporter (Oat1-3; Slc22a6-8) mRNA levels. *Drug Metab Dispos* **32**(6):620-5 (2004).
2. Cherrington N. J., *et al.* Lipopolysaccharide-mediated regulation of hepatic transporter mRNA levels in rats. *Drug Metab Dispos* **32**(7):734-41 (2004).
3. Dieter M. Z., *et al.* Expression and regulation of the sterol half-transporter genes ABCG5 and ABCG8 in rats. *Comp Biochem Physiol C Toxicol Pharmacol* **139**(4):209-18 (2004).
4. Gruber J. Functional gene analysis in cultured vertebrate cells using siRNA mediated gene silencing. (2004).
5. Heijne W. H., *et al.* Bromobenzene-induced hepatotoxicity at the transcriptome level. *Toxicol Sci* **79**(2):411-22 (2004).
6. Li N., *et al.* Down-regulation of mouse organic anion-transporting polypeptide 4 (Oatp4; Oatp1b2; Slc21a10) mRNA by lipopolysaccharide through the toll-like receptor 4 (TLR4). *Drug Metab Dispos* **32**(11):1265-71 (2004).
7. Li N., Klaassen C. D. Role of liver-enriched transcription factors in the down-regulation of organic anion transporting polypeptide 4 (oatp4; oatp1b2; slc21a10) by lipopolysaccharide. *Mol Pharmacol* **66**(3):694-701 (2004).
8. Lu H., Chen C., Klaassen C. Tissue distribution of concentrative and equilibrative nucleoside transporters in male and female rats and mice. *Drug Metab Dispos* **32**(12):1455-61 (2004).
9. Reynolds A., *et al.* Rational siRNA design for RNA interference. *Nat Biotechnol* **22**(3):326-30 (2004).

QuantiGene® 2.0 Bibliography

10. Sakamoto S., *et al.* Increased expression of CYR61, an extracellular matrix signaling protein, in human benign prostatic hyperplasia and its regulation by lysophosphatidic acid. *Endocrinology* **145**(6):2929-40 (2004).
11. Soutschek J., *et al.* Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. *Nature* **432**(7014):173-8 (2004).
12. Wright S. H., *et al.* Functional map of TEA transport activity in isolated rabbit renal proximal tubules. *Am J Physiol Renal Physiol* **287**(3):F442-51 (2004).

2003

1. Bramlett K. S., *et al.* A natural product ligand of the oxysterol receptor, liver X receptor. *J Pharmacol Exp Ther* **307**(1):291-6 (2003).
2. Buist S. C., Cherrington N. J., Klaassen C. D. Endocrine regulation of rat organic anion transporters. *Drug Metab Dispos* **31**(5):559-64 (2003).
3. Cao G., *et al.* Antidiabetic action of a liver x receptor agonist mediated by inhibition of hepatic gluconeogenesis. *J Biol Chem* **278**(2):1131-6 (2003).
4. Chen C., Hennig G. E., Manautou J. E. Hepatobiliary excretion of acetaminophen glutathione conjugate and its derivatives in transport-deficient (TR-) hyperbilirubinemic rats. *Drug Metab Dispos* **31**(6):798-804 (2003).
5. Chen C., Staudinger J. L., Klaassen C. D. Nuclear receptor, pregnane X receptor, is required for induction of UDP-glucuronosyltransferases in mouse liver by pregnenolone-16 alpha-carbonitrile. *Drug Metab Dispos* **31**(7):908-15 (2003).
6. Cherrington N. J., *et al.* Induction of multidrug resistance protein 3 (mrp3) in vivo is independent of constitutive androstane receptor. *Drug Metab Dispos* **31**(11):1315-9 (2003).
7. Choudhuri S., *et al.* Constitutive expression of various xenobiotic and endobiotic transporter mRNAs in the choroid plexus of rats. *Drug Metab Dispos* **31**(11):1337-45 (2003).
8. Khvorova A., Reynolds A., Jayasena S. D. Functional siRNAs and miRNAs exhibit strand bias. *Cell* **115**(2):209-16 (2003).
9. Leazer T. M., Klaassen C. D. The presence of xenobiotic transporters in rat placenta. *Drug Metab Dispos* **31**(2):153-67 (2003).
10. Sakamoto S., *et al.* Development of quantitative detection assays for CYR61 as a new marker for benign prostatic hyperplasia. *J Biomol Screen* **8**(6):701-11 (2003).
11. Shelby M. K., *et al.* Tissue mRNA expression of the rat UDP-glucuronosyltransferase gene family. *Drug Metab Dispos* **31**(3):326-33 (2003).
12. Slitt A. L., *et al.* Induction of multidrug resistance protein 3 in rat liver is associated with altered vectorial excretion of acetaminophen metabolites. *Drug Metab Dispos* **31**(9):1176-86 (2003).
13. Tsai S. P., *et al.* Nucleic acid capture assay, a new method for direct quantitation of nucleic acids. *Nucleic Acids Res* **31**(6):e25 (2003).

QuantiGene® 2.0 Bibliography

14. Wu S. J., *et al.* Quantitation of CYP1A1 and 1B1 mRNA in polycyclic aromatic hydrocarbon-treated human T-47D and HepG2 cells by a modified bDNA assay using fluorescence detection. *Anal Biochem* **312**(2):162-6 (2003).

2002

1. Bader T., *et al.* Human adipose tissue under in vitro inhibition of 11beta-hydroxysteroid dehydrogenase type 1: differentiation and metabolism changes. *Horm Metab Res* **34**(11-12):752-7 (2002).
2. Brady J. M., *et al.* Tissue distribution and chemical induction of multiple drug resistance genes in rats. *Drug Metab Dispos* **30**(7):838-44 (2002).
3. Buist S. C., *et al.* Gender-specific and developmental influences on the expression of rat organic anion transporters. *J Pharmacol Exp Ther* **301**(1):145-51 (2002).
4. Cherrington N. J., *et al.* Organ distribution of multidrug resistance proteins 1, 2, and 3 (Mrp1, 2, and 3) mRNA and hepatic induction of Mrp3 by constitutive androstane receptor activators in rats. *J Pharmacol Exp Ther* **300**(1):97-104 (2002).
5. Czerwinski M., *et al.* Analysis of CYP mRNA expression by branched DNA technology. *Methods Enzymol* **357**:170-9 (2002).
6. Guo G. L., Choudhuri S., Klaassen C. D. Induction profile of rat organic anion transporting polypeptide 2 (oatp2) by prototypical drug-metabolizing enzyme inducers that activate gene expression through ligand-activated transcription factor pathways. *J Pharmacol Exp Ther* **300**(1):206-12 (2002).
7. Guo G. L., Johnson D. R., Klaassen C. D. Postnatal expression and induction by pregnenolone-16alpha-carbonitrile of the organic anion-transporting polypeptide 2 in rat liver. *Drug Metab Dispos* **30**(3):283-8 (2002).
8. Harstad E. B., Klaassen C. D. Analysis of strain difference in sensitivity to cadmium-induced hepatotoxicity in Fischer 344 and Sprague-Dawley rats. *Toxicol Sci* **67**(2):329-40 (2002).
9. Johnson D. R., Guo G. L., Klaassen C. D. Expression of rat Multidrug Resistance Protein 2 (Mrp2) in male and female rats during normal and pregnenolone-16alpha-carbonitrile (PCN)-induced postnatal ontogeny. *Toxicology* **178**(3):209-19 (2002).
10. Johnson D. R., Habeebu S. S., Klaassen C. D. Increase in bile flow and biliary excretion of glutathione-derived sulfhydryls in rats by drug-metabolizing enzyme inducers is mediated by multidrug resistance protein 2. *Toxicol Sci* **66**(1):16-26 (2002).
11. Johnson D. R., Klaassen C. D. Regulation of rat multidrug resistance protein 2 by classes of prototypical microsomal enzyme inducers that activate distinct transcription pathways. *Toxicol Sci* **67**(2): 182-9 (2002).
12. Leazer T. M., Liu Y., Klaassen C. D. Cadmium absorption and its relationship to divalent metal transporter-1 in the pregnant rat. *Toxicol Appl Pharmacol* **185**(1):18-24 (2002).
13. Li N., *et al.* Tissue expression, ontogeny, and inducibility of rat organic anion transporting polypeptide 4. *J Pharmacol Exp Ther* **301**(2):551-60 (2002).

QuantiGene® 2.0 Bibliography

14. Luckey S. W., *et al.* 4-hydroxynonenal decreases interleukin-6 expression and protein production in primary rat Kupffer cells by inhibiting nuclear factor-kappaB activation. *J Pharmacol Exp Ther* **302**(1):296-303 (2002).
15. Luo G., *et al.* CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. *Drug Metab Dispos* **30**(7):795-804 (2002).
16. Park J. D., Cherrington N. J., Klaassen C. D. Intestinal absorption of cadmium is associated with divalent metal transporter 1 in rats. *Toxicol Sci* **68**(2):288-94 (2002).
17. Park J. D., Habeebu S. S., Klaassen C. D. Testicular toxicity of di-(2-ethylhexyl)phthalate in young Sprague-Dawley rats. *Toxicology* **171**(2-3):105-15 (2002).
18. Slitt A. L., *et al.* Tissue distribution and renal developmental changes in rat organic cation transporter mRNA levels. *Drug Metab Dispos* **30**(2):212-9 (2002).
19. Vansell N. R., Klaassen C. D. Increase in rat liver UDP-glucuronosyltransferase mRNA by microsomal enzyme inducers that enhance thyroid hormone glucuronidation. *Drug Metab Dispos* **30**(3):240-6 (2002).
20. Wagaman P. C., Leong M. A., Simmen K. A. Development of a novel influenza A antiviral assay. *J Virol Methods* **105**(1):105-14 (2002).
21. Xiang H., *et al.* Enhanced tumor killing by Apo2L/TRAIL and CPT-11 co-treatment is associated with p21 cleavage and differential regulation of Apo2L/TRAIL ligand and its receptors. *Oncogene* **21**(22):3611-9 (2002).
22. Zhang Y., *et al.* Liver X receptor and retinoic X receptor mediated ABCA1 regulation and cholesterol efflux in macrophage cells-messenger RNA measured by branched DNA technology. *Mol Genet Metab* **77**(1-2):150-8 (2002).

2001

1. Allan G. F., *et al.* Induction of the progesterone receptor gene in estrogen target cells monitored by branched DNA signal amplification. *Steroids* **66**(9):663-71 (2001).
2. Player A. N., *et al.* Single-copy gene detection using branched DNA (bDNA) in situ hybridization. *J Histochem Cytochem* **49**(5):603-12 (2001).
3. Rausch-Derra L. C., *et al.* Differential effects of microsomal enzyme-inducing chemicals on the hepatic expression of rat organic anion transporters, OATP1 and OATP2. *Hepatology* **33**(6):1469-78 (2001).
4. Sen A., *et al.* Adipogenic potential of human adipose derived stromal cells from multiple donors is heterogeneous. *J Cell Biochem* **81**(2):312-9 (2001).
5. Takiguchi M., *et al.* Cyproterone acetate induces a cellular tolerance to cadmium in rat liver epithelial cells involving reduced cadmium accumulation. *Toxicology* **165**(1):13-25 (2001).

2000

QuantiGene® 2.0 Bibliography

1. Bramlett K. S., Yao S., Burris T. P. Correlation of farnesoid X receptor coactivator recruitment and cholesterol 7alpha-hydroxylase gene repression by bile acids. *Mol Genet Metab* **71**(4):609-15 (2000).
2. Hartley D. P., Klaassen C. D. Detection of chemical-induced differential expression of rat hepatic cytochrome P450 mRNA transcripts using branched DNA signal amplification technology. *Drug Metab Dispos* **28**(5):608-16 (2000).
3. Warrior U., et al. Application of QuantiGene nucleic acid quantification technology for high throughput screening. *J Biomol Screen* **5**(5):343-52 (2000).
4. Wentworth J. M., Burris T. P., Chatterjee V. K. HIV protease inhibitors block human preadipocyte differentiation, but not via the PPARgamma/RXR heterodimer. *J Endocrinol* **164**(2):R7-10 (2000).
5. Zhou L., et al. A branched DNA signal amplification assay to quantitate messenger RNA of human uncoupling proteins 1, 2, and 3. *Anal Biochem* **282**(1):46-53 (2000).

1999

1. Burris T. P., et al. A novel method for analysis of nuclear receptor function at natural promoters: peroxisome proliferator-activated receptor gamma agonist actions on aP2 gene expression detected using branched DNA messenger RNA quantitation. *Mol Endocrinol* **13**(3):410-7 (1999).
2. Todd M. D., et al. Toxicity Screening of a Combinatorial Library: Correlation of Cytotoxicity and Gene Induction to Compound Structure. *J Biomol Screen* **4**(5):259-68 (1999).